PeptidesDNA verdict
PeptidesDNA is the clearest option for self-directed peptide researchers who already have a 23andMe or AncestryDNA file and want a structured, evidence-tiered read of how their genetics relate to specific compounds. The $99 flat fee and no-subscription model are genuinely fair for what you get, but the report stops at genetics education and explicitly does not provide dosing guidance, which limits its utility for anyone expecting clinical direction. If you need a general-purpose productivity or writing tool, this is the wrong category entirely; the directory competitors listed serve completely different use cases.
Strengths
One-time $99 flat fee with no subscription and an explicit data-deletion option covers a genuinely niche gap that no general productivity tool addresses.
Pharmacogenomics grounding is real: 8 pharmacogenes called against CPIC and PharmGKB star-allele definitions, cross-referenced with NCBI SNP data and PubMed literature, not LLM-generated text.
Weaknesses
The report covers only 39 peptides; a researcher interested in compounds outside that panel gets nothing, and there is no published list of which peptides are excluded or why.
No free tier and no trial report beyond the sample PDF means buyers must commit $99 before seeing how their own data actually renders, which is a meaningful ask for a single-use product.
LifeFrom verdict
LifeFrom is the most ambitious personal health record app currently in free beta, built for people who already have blood panels, DNA raw data, and wearables and want one place that reads them together. Its Apple Health dependency and iOS-only data pipeline mean Android users and anyone without lab data get far less value. If you want a general-purpose health chat assistant rather than a longitudinal biological record, ChatGPT or Claude will serve you better without requiring you to upload sensitive medical files.
Strengths
Reads blood panels, raw DNA variants, microbiome reports, and medical scans together in one record rather than treating each as a separate app silo.
Daily metabolic age recalculation from Apple Health data gives a continuously updated biological baseline, not a one-time snapshot.
Weaknesses
The entire metabolic age engine and daily recalculation pipeline depend on Apple Health, which locks out Android users completely and makes the core value proposition unavailable to roughly half the smartphone market.
Beta status means no disclosed post-beta pricing, no stated data-retention guarantees, and no published uptime or continuity commitments, which is a real risk when users are uploading MRI scans and raw DNA files.
